FDA Helps Makena With Statement Against High-Volume Compounding
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says it could take enforcement action against pharmacies producing large quantities of the preterm birth drug and physicians should prescribe an approved drug before a compounded version.
You may also be interested in...
Cheap Drugs Create Quality Temptations, FDA Official Says
FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.
Cheap Drugs Create Quality Temptations, FDA Official Says
FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.
Bankrupt KV Pharma’s Hopes For Makena Rest With Skeptical Judge
During a hearing in the company’s lawsuit against FDA, a federal judge repeatedly questions her authority to require the agency take enforcement action against compounding pharmacies; KV filed for bankruptcy protection three days earlier, citing its inability to realize full value of the pre-term birth drug due to competition from cheaper compounded versions of 17-P.